Response to ragweed allergen provocation in the Red Maple Trials Allergen Challenge TheatreTM
Poster Feb 24, 2015
Suzanne Kelly, PHD;Jacob Karsh, MDCM, FRCPC; Jimmy Yang, MBA; William H. Yang, MD, FRCPC, FAAAAI
Rationale: Allergen challenge chambers expose allergen-sensitive subjects to a predetermined concentration of allergen in a closed, controlled environment and provide a mechanism to induce clinical symptoms and measure the effect of medication.
Methods: We evaluated the response of ragweed-allergic subjects to two ragweed challenges in the Red Maple Trials Allergen Challenge Theatre. A provincial Ethics Board approved the study. After signing informed consent, patients with a history of ragweed allergy, not on allergy medications and with a positive skin prick test to ragweed antigen (> 3 mm) were exposed to ragweed pollen in a 3-hour priming session. Total nasal (TNSS), ocular and respiratory symptom scores (TRSS) were recorded at baseline and every 30 minutes during the challenge. Those with a TNSS > were then selected for 2 further 4-hour challenges.
Results: 48/76 subjects evaluated underwent the priming challenge. Thirty-three subjects achieving a peak TNSS ≥5 were selected for two subsequent 4-hour challenges. Baseline TNSS (mean± SD) was 1.70 ±1.34 and 2.53±1.76 in challenges 1 and 2, respectively. Baseline TRSS values were 2.00± 1.66 and 3.60±2.69 respectively. Symptom scores reached a plateau by 120 minutes and remained steady for the remainder of the 240-minute exposure period. Plateau TNSS was 6.28±0.20 for Challenge 1and 6.19±0.24 for Challenge 2. Similarly, TRSS values were 9.10±0.20 and 9.11± 0.33, respectively.
Conclusions: The Red Maple Trials allergen exposure theatre demonstrated the capacity to induce symptoms of appropriate intensity upon allergen challenge. Our chamber with a seating capacity of 100 places has the ability to evaluate large test groups at a time.
Genome-wide association studies (GWAS) have identified more than 100 genetic loci associated with type 2 diabetes. The majority of these are located in the intergenic or intragenic regions suggesting that the implicated variants may alter chromatin conformation. This, in turn, is likely to influence the expression of nearby or more remotely located genes to alter beta cell function. At present, however, detailed molecular and functional analyses are still lacking for most of these variants. We recently analysed one of these loci and mapped five causal variants in an islet-specific enhancer cluster within the STARD10 gene locus. Here, we aimed to understand how these causal variants influence b-cell function by alteration of the chromatin structure of enhancer clusterREAD MORE
This abstract discusses three cases of pediatric heart transplant patients who suffered from parvovirus (B19) infection. Of these patients, two ( B & C) responded well to standard intravenous Ig therapy. Patient A however, did not respond to standard treatment and was begun on subcutaneous Ig, which effectively diminished his viral load. Thus, subcutaneous Ig infusions might serve as a second line treatment for transplant patients with parvovirus who do not respond well to the standard approach.READ MORE